The Effect of Renastart Formula Supplementation in Children With Acute Kidney Injury in Maintaining Normal Serum Electrolytes Levels
NCT ID: NCT06218212
Last Updated: 2024-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2022-02-12
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multicenter Study to Evaluate the Nutritional Suitability of Renastart
NCT02825784
Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients
NCT05577507
Alpha Lipoic Acid in Pediatrics on Hemodialysis
NCT06286098
Effect of Omega 3 on Oxidative Stress and Nutritional Status of Children on Regular Dialysis
NCT06268184
Carnitine Supplementation in Pediatric Hemodialysis Patients
NCT05948124
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1 patients with AKI and acute on top of CKD who will be treated by electrolytes binders.
they will start calcium carbonate (phosphorus binder) with dosage 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.
calcium carbonate (phosphorus binder) with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.
calcium carbonate (phosphorus binder) in dosage of 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) in dosage of 0.5-1mg/kg/day orally.
Arm 2 patients with AKI and acute on top of CKD who will be treated by Renastart formula.
* Renastart formula will be used with breast milk, standard infant formula or with diet.
* Preparation: Adding one level scoop of Renastart to 30 ml water.
* Renastart formula will be started to represent ¼ recommended daily allowance of daily caloric intake and the dose will be adjusted according to serum electrolyte levels.
Renastart formula
* Renastart formula is an artificial formula is made by Vitaflo USA, Nestle Health Science Company.
* Renastart formula preparation: Adding one level scoop of Renastart to 30 ml water.
* Renastart formula will be used with breast milk, standard infant formula, standard pediatric infant feed and/ or mixed with diet.
* Renastart formula dosage will be adjusted to be 1/4 Renastart and 3/4 breast milk, standard infant formula or standard pediatric infant daily caloric feed ratio.
* Readjusting dosage ratio according to serum electrolytes levels especially potassium.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Renastart formula
* Renastart formula is an artificial formula is made by Vitaflo USA, Nestle Health Science Company.
* Renastart formula preparation: Adding one level scoop of Renastart to 30 ml water.
* Renastart formula will be used with breast milk, standard infant formula, standard pediatric infant feed and/ or mixed with diet.
* Renastart formula dosage will be adjusted to be 1/4 Renastart and 3/4 breast milk, standard infant formula or standard pediatric infant daily caloric feed ratio.
* Readjusting dosage ratio according to serum electrolytes levels especially potassium.
calcium carbonate (phosphorus binder) with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.
calcium carbonate (phosphorus binder) in dosage of 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) in dosage of 0.5-1mg/kg/day orally.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pediatric patients with coexisting another medical problems and different risk factors which can affect serum electrolytes such as: Constipation, high volume blood transfusion and Diabetes medications disrupt potassium balance e.g., ACEI, ARBS and Diuretics.
1 Month
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Haya Essam Ibrahim
lecturer of pediatrics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Haya E Ibrahim, MD
Role: PRINCIPAL_INVESTIGATOR
lecturer of pediatrics,Faculty of Medicine, Ain shams University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine-Ain Shams University
Cairo, Abbasia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASU MS 643/ 2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.